Yesterday, Espial announced that it had received notice from shareholder Vantage Asset Management of four director nominees who may be put forward for election to the board of directors at the coming annual and special meeting of shareholders on June 13.
Kwan says he view this development as a positive that could unlock value.
“Low insider ownership creates opportunity for change,” says Kwan. “Although execution has improved in recent quarters, the shares have remained range-bound since Q4 FY2015 (following the plunge after the announcement of the potential loss of Rogers) which has likely frustrated certain shareholders and possibly helped lead to this vent. The low insider ownership (<5%) means Vantage has one less obstacle to implement the changes it desires.”
In a research update to clients today, Kwan maintained his “Buy” rating and one-year price target of $2.85 on Espial Group.
Kwan thinks Espial will post Adjusted EBITDA of negative $1.7-million on revenue of $38.3-million in fiscal 2017. He expects these numbers will improve to EBITDA of positive $8.3-million on a topline of $53.6-million the following year.
“Espial is attractively valued given a superior organic growth profile, pristine balance sheet, and discount valuation, with key near-term catalysts including Tier 1 customer wins and now shareholder activism potentially driving the stock out of its current (depressed) trading range,” Kwan says.
Tesla’s (Tesla Stock Quote, Chart, News, Analysts, Financials NASDAQ: TSLA) better-than-feared Q1 wasn’t enough to keep Roth Capital Partners from… [Read More]
Beacon Securities is initiating coverage of Colabor Group (Colabor Group Stock Quote, Chart, News, Analysts, Financials TSXV:GCL) with a "Buy"… [Read More]
Decibel Cannabis (Decibel Cannabis Stock Quote, Chart, News, Analysts, Financials TSXV:DB) is poised for a revaluation as it returns to… [Read More]
Ventum Capital Markets analyst Amr Ezzat is maintaining his "Buy" rating on 5N Plus (5N Plus Stock Quote, Chart, News,… [Read More]
In his April 21 first-quarter preview, Rohit Kulkarni, Managing Director and Senior Research Analyst at Roth Capital Partners maintained his… [Read More]
Raymond James bullish rating for Bausch Health Companies (Bausch Health Companies NAME Stock Quote, Chart, News, Analysts, Financials NYSE:BHC) remains… [Read More]